Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.
Animals
Asthma
/ drug therapy
COVID-19
/ complications
Cells, Cultured
Disease Models, Animal
Drug Carriers
/ chemistry
Drug Compounding
Humans
Hydrogels
/ chemistry
Instillation, Drug
Mice
Microspheres
Mucus
/ drug effects
Nanospheres
/ administration & dosage
Niclosamide
/ administration & dosage
Pneumonia
/ drug therapy
Polyethylene Glycols
/ chemistry
Respiratory Mucosa
/ drug effects
Respiratory System
/ drug effects
SARS-CoV-2
/ drug effects
Trachea
COVID-19 Drug Treatment
COVID-19
TMEM16A
TMEM16F
asthma
hydrospheres
inflammatory airway disease
nanospheres
niclosamide
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Jan 2022
19 Jan 2022
Historique:
received:
30
11
2021
revised:
03
01
2022
accepted:
17
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
17
2
2022
Statut:
epublish
Résumé
Repurposing of the anthelminthic drug niclosamide was proposed as an effective treatment for inflammatory airway diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Niclosamide may also be effective for the treatment of viral respiratory infections, such as SARS-CoV-2, respiratory syncytial virus, and influenza. While systemic application of niclosamide may lead to unwanted side effects, local administration via aerosol may circumvent these problems, particularly when the drug is encapsulated into small polyethylene glycol (PEG) hydrospheres. In the present study, we examined whether PEG-encapsulated niclosamide inhibits the production of mucus and affects the pro-inflammatory mediator CLCA1 in mouse airways in vivo, while effects on mucociliary clearance were assessed in excised mouse tracheas. The potential of encapsulated niclosamide to inhibit TMEM16A whole-cell Cl
Identifiants
pubmed: 35163010
pii: ijms23031085
doi: 10.3390/ijms23031085
pmc: PMC8835663
pii:
doi:
Substances chimiques
Drug Carriers
0
Hydrogels
0
Polyethylene Glycols
3WJQ0SDW1A
Niclosamide
8KK8CQ2K8G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CF-Trust UK
ID : SRC013
Organisme : Deutsche Forschungsgemeinschaft
ID : KU756/14-1
Organisme : Gilead Sciences (Germany)
ID : Mucus
Références
J Pharm Sci. 2012 Feb;101(2):566-75
pubmed: 21997465
FASEB J. 2016 Feb;30(2):727-37
pubmed: 26481309
Front Pharmacol. 2019 Feb 14;10:51
pubmed: 30837866
J Biol Chem. 1985 Mar 25;260(6):3440-50
pubmed: 3838314
Sci Rep. 2019 Jul 25;9(1):10822
pubmed: 31346185
Lancet Reg Health Eur. 2021 May;4:100094
pubmed: 33870260
Nat Commun. 2015 Feb 05;6:6245
pubmed: 25651887
J Biol Chem. 2012 May 18;287(21):17530-17545
pubmed: 22474287
Nat Commun. 2016 May 10;7:11523
pubmed: 27161080
J Clin Lab Anal. 2004;18(2):91-128
pubmed: 15065212
Angew Chem Int Ed Engl. 2010 Feb 22;49(9):1540-73
pubmed: 20166107
Clin Exp Allergy. 2017 Jun;47(6):795-804
pubmed: 28109183
Eur J Pharmacol. 2020 Nov 15;887:173438
pubmed: 32795515
Soft Matter. 2019 Jan 28;15(4):709-720
pubmed: 30624437
Elife. 2015 Mar 17;4:
pubmed: 25781344
Cells. 2019 Dec 30;9(1):
pubmed: 31905994
J Med Virol. 2021 Oct;93(10):5825-5832
pubmed: 34061377
Front Pharmacol. 2019 Jan 29;10:3
pubmed: 30761000
Pflugers Arch. 2016 Mar;468(3):475-90
pubmed: 26700940
Sci Rep. 2016 Aug 16;6:31562
pubmed: 27527926
Cancers (Basel). 2019 May 05;11(5):
pubmed: 31060306
Int J Mol Sci. 2021 Jul 22;22(15):
pubmed: 34360618
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066250
Thorax. 2021 Jan;76(1):64-72
pubmed: 33109690
Drug Dev Ind Pharm. 2015;41(9):1416-24
pubmed: 25204767
Am J Respir Crit Care Med. 2020 Apr 15;201(8):946-954
pubmed: 31898911
Int J Pharm. 2019 Jul 20;566:652-661
pubmed: 31181308
Int J Pharm. 2005 Nov 4;304(1-2):193-209
pubmed: 16198076
J Mol Biol. 2021 Oct 1;:167280
pubmed: 34606831
Am J Respir Cell Mol Biol. 1997 Jan;16(1):14-22
pubmed: 8998074
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16354-9
pubmed: 22988107
Macromolecules. 2011 Sep 27;44(18):7132-7140
pubmed: 22287809
PLoS One. 2013 Oct 25;8(10):e77730
pubmed: 24204939
Biomacromolecules. 2021 Aug 9;22(8):3223-3236
pubmed: 34270216
Int J Mol Sci. 2020 Apr 07;21(7):
pubmed: 32272686
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
JCI Insight. 2019 Aug 8;4(15):
pubmed: 31391337
Pflugers Arch. 2018 Feb;470(2):305-314
pubmed: 28875346
Nature. 2021 Jun;594(7861):88-93
pubmed: 33827113
FASEB J. 2017 May;31(5):2123-2134
pubmed: 28183802
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
Cell Physiol Biochem. 2021 Oct 13;55(5):590-604
pubmed: 34637202
Bio Protoc. 2020 Mar 20;10(6):e3554
pubmed: 33659527
Physiol Rev. 2005 Jul;85(3):1061-92
pubmed: 15987802
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
J Microencapsul. 2015;32(5):496-502
pubmed: 26079596
Am J Respir Cell Mol Biol. 2021 Jan;64(1):50-58
pubmed: 33026825
J Control Release. 2010 Mar 3;142(2):221-8
pubmed: 19887092
Nat Commun. 2021 Jun 21;12(1):3818
pubmed: 34155207
Eur Respir J. 2021 Jul 8;58(1):
pubmed: 33361100
Inflamm Allergy Drug Targets. 2009 Jun;8(2):146-60
pubmed: 19530997
Ann Med Surg (Lond). 2021 Sep;69:102779
pubmed: 34512959
PLoS Pathog. 2021 Jul 12;17(7):e1009706
pubmed: 34252168
Pflugers Arch. 2008 Nov;457(2):431-40
pubmed: 18607626
PLoS One. 2015 Jun 29;10(6):e0131775
pubmed: 26121472
Cell. 2012 Sep 28;151(1):111-22
pubmed: 23021219
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Physiol. 2012 Dec 1;590(23):6141-55
pubmed: 22988141
Cell Signal. 2018 Apr;44:10-19
pubmed: 29331508
Lancet Reg Health Eur. 2021 May;4:100084
pubmed: 33842908
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Acta Biomater. 2021 Jan 1;119:13-29
pubmed: 33141051
Exp Eye Res. 2020 Sep;198:108151
pubmed: 32721426
Nanoscale. 2021 Apr 7;13(13):6410-6416
pubmed: 33885522
J Biomater Appl. 2019 Nov;34(5):617-630
pubmed: 31357900